Caspofungin acetate adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Caspofungin acetate
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Generic name
Class: Echinocandin antifungal

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From February 2004 to June 2026, FDA received 1,011 adverse event reports that name Caspofungin acetate. In these reports the drug is a suspect or interacting product.

In the same period, 546 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 94 reports in the 12 months to June 2026 and 97 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Caspofungin acetate is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

No update is on record for this page. The record starts when FDA adds the reports of July to September 2026.

In April to June 2026, FDA received 22 reports that name Caspofungin acetate.
In January to March 2026, FDA received 20.
In April to June 2025, FDA received 18.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 114 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 979 of the 1,011 reports (96.8%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 114 terms.

Reaction terms in the reports that name Caspofungin acetate, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 1,011 reports
Drug ineffectivethe medicine did not work as expected	321	31.8%
Multiple organ dysfunction syndromeseveral organs failing	63	6.2%
Off label useused for a purpose or in a way not on the label	56	5.5%
Drug resistance	54	5.3%
Product use in unapproved indicationused for a purpose not on the label	53	5.2%
Septic shockshock arising from infection	49	4.8%
Systemic candida	46	4.5%
Pathogen resistance	42	4.2%
Candida infectionthrush, a yeast infection	40	4%
Aspergillus infection	39	3.9%
Deaththe patient died; cause not stated by this term	35	3.5%
Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement	33	3.3%
Agranulocytosis	32	3.2%
Condition aggravatedthe condition being treated got worse	32	3.2%
Systemic mycosis	32	3.2%
Drug interactionan interaction between medicines	30	3%
Acute kidney injurysudden loss of kidney function	29	2.9%
Sepsisa severe body-wide response to infection	27	2.7%
Toxic epidermal necrolysisa severe skin reaction with peeling	25	2.5%
Bronchopulmonary aspergillosis	24	2.4%
Fungal infectiona fungal infection	23	2.3%
Actinic keratosis	21	2.1%
Dysplastic naevus	21	2.1%
Febrile neutropeniafever with low white blood cells	21	2.1%
Neutropenialow neutrophils, a type of white blood cell	21	2.1%
Photodermatosis	21	2.1%
Photosensitivity reactionskin reaction to sunlight	21	2.1%
Renal failurekidney failure	21	2.1%
Solar lentigo	21	2.1%
Squamous cell carcinoma of skin	21	2.1%
Pneumonialung infection	20	2%
Eosinophilia	19	1.9%
Pyrexiafever	19	1.9%
Rash maculo-papulara rash of flat and raised spots	19	1.9%
Treatment failurethe treatment did not work	18	1.8%
Bacteraemia	16	1.6%
Bacterial infectiona bacterial infection	15	1.5%
Respiratory failurethe lungs could not supply enough oxygen	14	1.4%
Haematological infection	13	1.3%
Myelosuppression	13	1.3%
Protothecosis	13	1.3%
Renal impairmentreduced kidney function	13	1.3%
Scedosporium infection	13	1.3%
Staphylococcal bacteraemia	13	1.3%
Stevens-Johnson syndromea severe skin and mucous-membrane reaction	13	1.3%
Therapy non-responderthe treatment did not work	13	1.3%
Central nervous system fungal infection	12	1.2%
Haemoglobin decreasedlow haemoglobin	12	1.2%
Hepatotoxicityliver injury	12	1.2%
Liver abscess	12	1.2%

Download all 114 terms of Caspofungin acetate (CSV)

The counts add to more than 1,011 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Same ingredient, other names

Reporters write a brand name or a generic name. Each name has its own page and its own count.

Names of Caspofungin acetate with a page, in the order generic names, brand names, names as reported
Name	Name type	Reports
Caspofungin acetate (this page)	Generic name	1,011
Cancidas	Brand name	2,296

Sum of the separately reported names: 3,307. A report that names two of these names is in the sum two times. The sum is not the number of reports for the ingredient.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Caspofungin acetate, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Other Serious (Important Medical Events)	Not serious
2004	6	6	6	2	3	1	3	0
2005	2	2	2	0	1	0	0	0
2006	1	1	0	0	1	0	0	0
2007	8	8	3	1	4	1	5	0
2008	4	4	3	0	1	0	2	0
2009	11	11	3	1	7	1	3	0
2010	18	18	4	7	8	0	10	0
2011	22	21	10	2	6	0	7	1
2012	18	18	10	1	6	0	12	0
2013	24	18	9	6	5	1	8	6
2014	33	27	15	4	6	1	12	6
2015	51	46	28	2	19	1	10	5
2016	17	17	9	2	7	0	11	0
2017	32	31	18	2	13	1	19	1
2018	77	74	42	10	14	1	54	3
2019	84	79	16	3	21	1	65	5
2020	66	62	21	3	26	0	43	4
2021	61	59	25	4	26	0	41	2
2022	84	82	25	4	34	0	57	2
2023	76	75	14	4	29	2	52	1
2024	107	107	12	15	40	2	90	0
2025	157	145	43	20	51	1	91	12
2026	52	52	17	5	14	0	39	0

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Caspofungin acetate, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Caspofungin acetate, by the year in which FDA received them
Year	Reports
2004	6
2005	3
2006	3
2007	9
2008	6
2009	13
2010	18
2011	22
2012	22
2013	32
2014	31
2015	60
2016	20
2017	45
2018	100
2019	98
2020	74
2021	61
2022	78
2023	83
2024	97
2025	88
2026	42

Reports that name Caspofungin acetate, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Caspofungin acetate
Age	Reports	Share
Under 2	18	1.8%
2 to 11	99	9.8%
12 to 17	69	6.8%
18 to 44	137	13.6%
45 to 64	335	33.1%
65 to 74	130	12.9%
75 and over	100	9.9%
Age not given	123	12.2%

Sex of the patient in the reports that name Caspofungin acetate
Sex	Reports	Share
Female	360	35.6%
Male	549	54.3%
Unknown or not given	102	10.1%

Type of reporter in the reports that name Caspofungin acetate
Reporter	Reports	Share
Physician	391	38.7%
Pharmacist	69	6.8%
Other health professional	460	45.5%
Lawyer	0	0%
Consumer or non-health professional	70	6.9%
Not given	21	2.1%

Age and sex are as the report gives them. The reporter is the primary source in the report. 7.5% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Caspofungin acetate record
Indication as recorded (MedDRA)	Reports	Share
Candida infection	91	9%
Antifungal prophylaxis	86	8.5%
Fungal infection	81	8%
Aspergillus infection	49	4.8%
Antifungal treatment	41	4.1%
Systemic candida	40	4%

The reporter fills in the indication, and the field is often empty. Each share is of all 1,011 reports.

Pages near this one

Cancidas same ingredient
Micafungin same class
Anidulafungin same class
Micafungin sodium same class
Caspofungin next in the A to Z list
Cataflam next in the A to Z list
Casodex next in the A to Z list
Catapres next in the A to Z list
Casirivimab/Imdevimab next in the A to Z list
Catapres-TTS-1 next in the A to Z list
Casirivimab Imdevimab next in the A to Z list
Catapresan next in the A to Z list

These links are for navigation. No count selected them. The class page lists each drug of the class.

Official pages

DailyMed labels for Caspofungin acetateThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Caspofungin acetate: adverse event reports that FDA received. https://reportedreactions.com/drug/caspofungin-acetate/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Caspofungin acetate as a suspect or interacting product. The 546 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Caspofungin acetate was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Caspofungin acetate?

No. It is a count of what people reported to FDA: 1,011 reports from February 2004 to June 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Other health professional (45.5%), physician (38.7%) and consumer or non-health professional (6.9%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page